Rigenerand Raises €8.7M in Venture Capital Funding

rigenerandRigenerand Srl, a Medolla (MO), Italy-based company committed to develop biomedical devices supporting the culture of stem cells for pre-clinical and clinical applications, raised €8.7m in venture capital funding.

Milan, Italy-based vc firm Principia SGR made the investment via Principia III – Healthcare.

The company intends to use the funds to invest in technology and realize a new “cell factory”.

Founded in 2009 by Prof. Massimo Dominici and Prof. Pierfranco Conte, as a spin-off resulting from a joint venture between biomedical company RanD and researchers from the University of Modena and Reggio Emilia, Rigenerand owns proprietary technology to develop and produce biomedical tools to empower the ex-vivo phase of stem cells expansion combining the need of high cell yield with innovative biocompatible materials.

The company, led by CEO Giorgio Mari, is now advancing two different projects.

Join the discussion